# **Special Issue**

# Anabolic Androgenic Steroids and Performance-Enhancing Drugs: Forensic Aspects, Collateral Effects, and Polypharmacy

## Message from the Guest Editor

The use of anabolic androgenic steroids and performance-enhancing drugs is an increasingly current and evolving topic. More and more young people are using and accessing these drugs, and sometimes abusing them. There is also an easily accessible and poorly controlled black market. The side effects are multiple and multisystemic, even unknown. As the , I would like to encourage you to submit research articles or comprehensive reviews or case reports to offer an overview of the use and side effects of anabolic androgenic steroids and performance-enhancing drugs, even in polypharmacy.

### **Guest Editor**

Dr. Massimiliano Esposito

Faculty of Medicine and Surgery, "Kore" University of Enna, 94100 Enna, Italy

### Deadline for manuscript submissions

closed (25 September 2024)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



### mdpi.com/si/201980

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

